Senhwa Biosciences Past Earnings Performance
Past criteria checks 0/6
Senhwa Biosciences has been growing earnings at an average annual rate of 5.5%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 16% per year.
Key information
5.5%
Earnings growth rate
10.6%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 16.0% |
| Return on equity | -22.5% |
| Net Margin | -29,630.6% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Senhwa Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -296 | 55 | 257 |
| 30 Sep 23 | 1 | -305 | 53 | 266 |
| 30 Jun 23 | 1 | -312 | 49 | 275 |
| 31 Mar 23 | 1 | -345 | 45 | 310 |
| 31 Dec 22 | 1 | -350 | 44 | 313 |
| 30 Sep 22 | 1 | -340 | 62 | 284 |
| 30 Jun 22 | 1 | -345 | 66 | 285 |
| 31 Mar 22 | 1 | -316 | 70 | 261 |
| 31 Dec 21 | 1 | -329 | 71 | 275 |
| 30 Sep 21 | 1 | -328 | 57 | 289 |
| 30 Jun 21 | 1 | -358 | 84 | 291 |
| 31 Mar 21 | 1 | -362 | 83 | 285 |
| 31 Dec 20 | 1 | -355 | 83 | 276 |
| 30 Sep 20 | 1 | -352 | 81 | 274 |
| 30 Jun 20 | 0 | -316 | 55 | 264 |
| 31 Mar 20 | 0 | -339 | 56 | 286 |
| 31 Dec 19 | 0 | -391 | 57 | 337 |
| 30 Sep 19 | 0 | -410 | 58 | 356 |
| 30 Jun 19 | 1 | -416 | 61 | 362 |
| 31 Mar 19 | 1 | -451 | 61 | 401 |
| 31 Dec 18 | 1 | -376 | 60 | 327 |
| 30 Sep 18 | 1 | -394 | 63 | 341 |
| 30 Jun 18 | 0 | -416 | 61 | 364 |
| 31 Mar 18 | 0 | -354 | 62 | 302 |
| 31 Dec 17 | 0 | -372 | 61 | 315 |
| 30 Sep 17 | 0 | -333 | 62 | 277 |
| 30 Jun 17 | 0 | -283 | 60 | 228 |
| 31 Mar 17 | 0 | -286 | 55 | 232 |
| 31 Dec 16 | 0 | -255 | 51 | 207 |
| 30 Sep 16 | 0 | -233 | 42 | 191 |
| 30 Jun 16 | 0 | -212 | 40 | 176 |
| 31 Mar 16 | 0 | -194 | 40 | 158 |
| 31 Dec 15 | 0 | -194 | 39 | 162 |
| 30 Sep 15 | 2 | -180 | 37 | 152 |
| 30 Jun 15 | 5 | -182 | 35 | 153 |
| 31 Mar 15 | 14 | -165 | 34 | 138 |
| 31 Dec 14 | 24 | -157 | 37 | 128 |
| 30 Sep 14 | 31 | -139 | 34 | 112 |
| 30 Jun 14 | 39 | -120 | 31 | 95 |
| 31 Mar 14 | 32 | -117 | 21 | 99 |
| 31 Dec 13 | 26 | -113 | 12 | 102 |
Quality Earnings: 6492 is currently unprofitable.
Growing Profit Margin: 6492 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6492 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.5% per year.
Accelerating Growth: Unable to compare 6492's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6492 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.1%).
Return on Equity
High ROE: 6492 has a negative Return on Equity (-22.5%), as it is currently unprofitable.